Diagnostic system provider AutoGenomics sets terms for $60 million IPO


Shutterstock photo

AutoGenomics, which provides a molecular diagnostics system for genetic testing in clinical laboratories, announced terms for its IPO on Wednesday. The Vista, CA-based company plans to raise $60 million by offering 6 million shares at a price range of $9 to $11. At the midpoint of the proposed range, AutoGenomics would command a fully diluted market value of $188 million. The company originally filed for an IPO in 2008 before withdrawing the registration in 2011. AutoGenomics, which was founded in 1999 and booked $17 million in sales for the 12 months ended 9/30/2012, plans to list on the NASDAQ under the symbol AGMX. Leerink Swann is the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com